KALA BIO, INC. Research and Development Expense
KALA BIO, INC. (KALA) reported Research and Development Expense of $59.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-19
- KALA BIO, INC. research and development expense for the quarter ending 2026-06-30 was $59.00K, a 99.05% decline year-over-year.
- KALA BIO, INC. research and development expense for the quarter ending 2026-03-31 was $61.00K, a 98.99% decline year-over-year.
- KALA BIO, INC. research and development expense for the quarter ending 2025-09-30 was $6.13M, a 18.56% increase year-over-year.
- KALA BIO, INC. research and development expense for the quarter ending 2025-06-30 was $6.23M, a 17.21% increase year-over-year.
- KALA BIO, INC. research and development expense for fiscal 2020 was $18.35M, a 32.71% decline from fiscal 2019.
- KALA BIO, INC. research and development expense for fiscal 2019 was $27.27M, a 6.88% decline from fiscal 2018.
- KALA BIO, INC. research and development expense for fiscal 2018 was $29.29M, a 0.97% increase from fiscal 2017.
- KALA BIO, INC. research and development expense for fiscal 2017 was $29.01M, a 15.90% increase from fiscal 2016.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $59.00K 10-Q · filed 2026-08-19 | $120.00K 10-Q · filed 2026-08-19 | ||
| 2026-03-31 | $61.00K 10-Q · filed 2026-05-15 | |||
| 2025-09-30 | $6.13M 10-Q · filed 2025-11-19 | $12.36M derived: sum of 2 quarters · filed 2026-08-19 | $18.41M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $6.23M 10-Q · filed 2026-08-19 | $12.29M 10-Q · filed 2026-08-19 | ||
| 2025-03-31 | $6.05M 10-Q · filed 2026-05-15 | |||
| 2024-09-30 | $5.17M 10-Q · filed 2025-11-19 | $10.48M derived: sum of 2 quarters · filed 2025-11-19 | $16.84M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $5.32M 10-Q · filed 2025-08-08 | $11.67M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $6.35M 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $5.55M 10-Q · filed 2024-11-12 | $9.83M derived: sum of 2 quarters · filed 2024-11-12 | $13.87M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $4.28M 10-Q · filed 2024-08-06 | $8.31M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $4.04M 10-Q · filed 2024-05-14 | |||
| 2022-09-30 | $5.39M 10-Q · filed 2023-11-13 | $9.86M derived: sum of 2 quarters · filed 2023-11-13 | $14.33M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $4.47M 10-Q · filed 2023-08-04 | $8.94M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $4.47M 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $2.88M 10-Q · filed 2022-11-08 | $5.97M derived: sum of 2 quarters · filed 2022-11-08 | $9.10M 10-Q · filed 2022-11-08 | $12.50M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.09M 10-Q · filed 2022-08-11 | $6.22M 10-Q · filed 2022-08-11 | $9.62M derived: sum of 3 quarters · filed 2022-08-11 | $13.09M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $3.13M 10-Q · filed 2022-05-16 | $6.52M derived: sum of 2 quarters · filed 2022-05-16 | $9.99M derived: sum of 3 quarters · filed 2022-05-16 | $16.04M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.87M derived: sum of 2 quarters · filed 2021-11-15 | $12.92M derived: sum of 3 quarters · filed 2021-11-15 | $18.35M 10-K · filed 2021-02-25 |
| 2020-09-30 | $3.47M 10-Q · filed 2021-11-15 | $9.52M derived: sum of 2 quarters · filed 2021-11-15 | $14.96M 10-Q · filed 2021-11-15 | $21.09M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $6.05M 10-Q · filed 2021-08-05 | $11.49M 10-Q · filed 2021-08-05 | $17.63M derived: sum of 3 quarters · filed 2021-08-05 | $24.70M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $5.43M 10-Q · filed 2021-05-05 | $11.57M derived: sum of 2 quarters · filed 2021-05-05 | $18.64M derived: sum of 3 quarters · filed 2021-05-05 | $25.75M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $13.21M derived: sum of 2 quarters · filed 2021-02-25 | $20.32M derived: sum of 3 quarters · filed 2021-02-25 | $27.27M 10-K · filed 2021-02-25 |
| 2019-09-30 | $7.07M 10-Q · filed 2020-11-05 | $14.18M derived: sum of 2 quarters · filed 2020-11-05 | $21.14M 10-Q · filed 2020-11-05 | $30.38M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $7.11M 10-Q · filed 2020-08-06 | $14.07M 10-Q · filed 2020-08-06 | $23.31M derived: sum of 3 quarters · filed 2020-08-06 | $30.33M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $6.96M 10-Q · filed 2020-05-07 | $16.20M derived: sum of 2 quarters · filed 2020-05-07 | $23.23M derived: sum of 3 quarters · filed 2020-05-07 | $30.59M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $16.27M derived: sum of 2 quarters · filed 2020-02-12 | $23.63M derived: sum of 3 quarters · filed 2020-02-12 | $29.29M 10-K · filed 2020-02-12 |
| 2018-09-30 | $7.03M 10-Q · filed 2019-11-07 | $14.39M derived: sum of 2 quarters · filed 2019-11-07 | $20.05M 10-Q · filed 2019-11-07 | $25.93M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $7.37M 10-Q · filed 2019-08-06 | $13.02M 10-Q · filed 2019-08-06 | $18.91M derived: sum of 3 quarters · filed 2019-08-06 | $25.92M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $5.66M 10-Q · filed 2019-05-09 | $11.54M derived: sum of 2 quarters · filed 2019-05-09 | $18.55M derived: sum of 3 quarters · filed 2019-05-09 | $26.63M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $12.90M derived: sum of 2 quarters · filed 2019-03-12 | $20.97M derived: sum of 3 quarters · filed 2019-03-12 | $29.01M 10-K · filed 2019-03-12 |
| 2017-09-30 | $7.02M 10-Q · filed 2018-11-08 | $15.09M derived: sum of 2 quarters · filed 2018-11-08 | $23.13M 10-Q · filed 2018-11-08 | $30.04M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $8.07M 10-Q · filed 2018-08-09 | $16.11M 10-Q · filed 2018-08-09 | $23.02M derived: sum of 3 quarters · filed 2018-08-09 | $31.28M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $8.04M 10-Q · filed 2018-05-10 | $14.95M derived: sum of 2 quarters · filed 2018-05-10 | $23.21M derived: sum of 3 quarters · filed 2018-05-10 | $29.16M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $15.17M derived: sum of 2 quarters · filed 2018-04-02 | $21.12M derived: sum of 3 quarters · filed 2018-04-02 | $25.03M 10-K · filed 2018-04-02 |
| 2016-09-30 | $8.26M 10-Q · filed 2017-11-07 | $14.21M derived: sum of 2 quarters · filed 2017-11-07 | $18.12M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $5.95M 10-Q · filed 2017-08-31 | $9.86M 10-Q · filed 2017-08-31 | ||
| 2015-12-31 | $11.38M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |